Neuroendocrine Tumours Market

• Neuroendocrine Tumors (NETs) represent a varied group of neoplasms that develop from tissues possessing neurological or endocrine functions. This broad category encompasses tumors that can originate from almost any organ system.
• The increase in Neuroendocrine Tumor Incidence rates over time is most pronounced in the GI tract, particularly in the large intestine (20%), small intestine (19%), and appendix (4%).
• The management of Neuroendocrine Tumor includes a variety of strategies, from conservative management for asymptomatic lesions to surgical resection for localized tumors. Major pharmaceutical Neuroendocrine Tumor Companies such as Novartis and Ipsen Biopharmaceuticals, play a significant role in offering treatments for the condition. Somatostatin analog (SSA) therapy is a key treatment along with, Peptide receptor radionuclide therapy (PRRT), Chemotherapy, and Immunotherapy.
• Somatostatin analogs are projected to capture a noteworthy Neuroendocrine Tumor Drugs Market Share of total therapy sales during the forecast period.
• In April 2024, Novartis announced that the US Food and Drug Administration (FDA) approved LUTATHERA for treating pediatric patients aged 12 and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors, including those in the foregut, midgut, and hindgut. This approval marks Lutathera as the first therapy specifically reviewed and approved for use in pediatric patients with gastroenteropancreatic neuroendocrine tumors.
• In February 2024, RadioMedix and Orano Med announced that the US FDA granted Breakthrough Therapy Designation (BTD) to AlphaMedix (212Pb-DOTAMTATE) for treating adult patients with unresectable or metastatic, progressive somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors who have not previously undergone peptide receptor radionuclide therapy (PRRT).
• The Neuroendocrine Tumor Treatment Market Landscape is evolving significantly, driven by advancements in treatment options and the active involvement of major pharmaceutical companies. Notably, companies such as Camurus and ITM Isotope Technologies Munich, among others, are leading research and development efforts aimed at enhancing treatment options and shaping market trends.
• The leading Neuroendocrine Tumor Companies such as Ipsen, Radiomedix Inc., Biotheus Inc., ITM Solucin GmbH, Sinotau Pharmaceutical Group, Clarity Pharmaceuticals Ltd, Aadi Bioscience Inc., Pfizer, Mateon Therapeutics, Hutchison Medipharma Limited, and others.

 Request for Unlocking the Sample Page of the "Neuroendocrine Tumor Treatment Market"

DelveInsight's “Neuroendocrine Tumor Treatment Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. 

Neuroendocrine Tumor Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Neuroendocrine Tumor market size from 2020 to 2034. The report also covers current Neuroendocrine Tumor Treatment Market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential. 

Neuroendocrine Tumor Treatment Market: Understanding and Algorithm

Neuroendocrine tumors are a group of uncommon tumors that start in specialized cells in the neuroendocrine system. These cells combine the traits of nerve cells and hormone-producing endocrine cells. Neuroendocrine cells receive and send messages through hormones to help the body function. Neuroendocrine cells are found in organs throughout the body. Neuroendocrine tumors often grow very slowly. In children and young adults, neuroendocrine tumors are most often found in the appendix, called appendiceal neuroendocrine tumors, or in the lungs, called bronchial tumors. In adults, neuroendocrine tumors are most often found in the digestive tract, called GI NET. This tumor may spread to other parts of the body.

Healthcare providers diagnose Neuroendocrine tumors based on the kind of neuroendocrine tumors they think one might have. The most commonly used tests include Biopsy, Core needle biopsy, Urinalysis, Computed tomography (CT) scan, Magnetic resonance imaging (MRI), and Positron emission testing (PET) scan. The Neuroendocrine Tumor Treatment Market Report provides an overview of neuroendocrine tumor pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Neuroendocrine Tumor Treatment

Surgery is the most common treatment for neuroendocrine tumors. If the tumors are large or have spread, other treatments might be necessary. Somatostatin analogs are a type of treatment that may stop the body from making too many hormones, potentially slowing down the growth of the tumor when cancer cells have metastasized. Targeted therapy uses drugs that focus on specific genes or proteins to kill cancer cells. Additionally, chemotherapy employs several types of drugs to kill cancer cells.

Neuroendocrine Tumor Epidemiology

The Neuroendocrine tumors epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Neuroendocrine tumor epidemiology is segmented with detailed insights into Total Neuroendocrine Tumors Incidence Cases, Neuroendocrine Tumors Grade-specific Cases, Neuroendocrine Tumors Tumor site-specific Cases, Neuroendocrine Tumors Stage-specific Cases, Neuroendocrine Tumors Symptom-specific Cases.

• It is estimated that neuroendocrine tumors are diagnosed more frequently in females.
• The most common sites of disease are the lung, rectum, and small intestine.
• The incidence of NETs continues to increase-particularly in older adults in the US.
• Age appears to be associated with a worse prognosis independent of neuroendocrine tumor stage, and grade at the time of diagnosis.

Neuroendocrine Tumor Drugs Market Chapters

The drug chapter segment of the Neuroendocrine Tumor Therapeutics Market Report encloses a detailed analysis of Neuroendocrine Tumor marketed drugs and late-stage (Phase III and Phase II) Neuroendocrine Tumor Pipeline Drugs analysis. It also deep dives into the Neuroendocrine Tumor Clinical Trials details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Neuroendocrine Tumor Marketed Drugs

• LUTATHERA: Novartis

Lutathera (lutetium Lu 177 dotatate*) is a lutetium Lu 177-labeled somatostatin analog peptide. Lutathera belongs to a class of treatments called Peptide Receptor Radionuclide Therapy (PRRT). Lutathera is comprised of a targeting molecule that carries a radioactive component. Lutathera has received orphan drug designation from the FDA and the European Medicines Agency (EMA). It was approved in 2018 by the US FDA for the treatment of adult patients with SSTR-positive GEP-NETs, including those in the foregut, midgut, and hindgut. Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptors (SSTR)-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs.

• SOMATULINE DEPOT: Ipsen Biopharmaceuticals

SOMATULINE DEPOT (lanreotide) is a somatostatin analog indicated for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced, or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival.

Neuroendocrine Tumor Emerging Drugs

• CAM2029: Camurus

CAM2029 is a long-acting octreotide subcutaneous depot under development for the treatment of three rare diseases: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD). Studies completed to date demonstrate that CAM2029 has the potential to provide significantly higher octreotide bioavailability and octreotide exposure with the potential for improved treatment efficacy, compared to current market-leading products. CAM2029 is designed to enable easy self-administration, including the option of a pre-filled pen. CAM2029 is based on Camurus' proprietary FluidCrystal technology. Currently, it is in Phase III of Neuroendocrine Tumor Clinical Trials development for the treatment of GEP-NET.

• ITM-11: ITM Isotope Technologies Munich

ITM-11 (177Lu-edotreotide), being developed by ITM Isotope Technologies Munich, is an innovative targeted radionuclide therapy agent consisting of two components: firstly, Edotreotide (DOTATOC), an octreotide-derived somatostatin analog, and secondly, EndolucinBeta (no-carrier-added (n.c.a.) lutetium-177 chloride) a synthetic, low-energy beta-emitting therapeutic radioisotope.. It is currently being investigated in two Phase III Neuroendocrine Tumor Clinical Trials, COMPETE (NCT03049189) and COMPOSE (NCT04919226). While COMPETE is evaluating ITM-11 for the treatment of patients with grade 1 and grade 2 GEP-NETs, the radiopharmaceutical candidate is also being investigated in COMPOSE, for patients with well-differentiated high grade 2 and grade 3 GEP-NETs. ITM-11 received an orphan designation as a treatment for GEP-NETs based on the data from a Phase II Neuroendocrine Tumor Clinical Trials study, which demonstrated a significant benefit (substantially improved progression-free survival, PFS).

Neuroendocrine Tumor Market Outlook

Key Neuroendocrine Tumor Companies, such as ITM Isotope Technologies Munich, Camurus, and others, are evaluating their lead candidates in different stages of Neuroendocrine Tumor Clinical Trials development, respectively. They aim to investigate their products for the Neuroendocrine Tumors.

Neuroendocrine Tumor Drugs Uptake

This section focuses on the uptake rate of potential Neuroendocrine Tumor drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Neuroendocrine Tumor Pipeline Development Activities

The Neuroendocrine Tumor Therapeutics Market Report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Neuroendocrine Tumor Companies involved in developing targeted therapeutics. 

Neuroendocrine Tumor Pipeline Development Activities

The Neuroendocrine Tumor Therapeutics Market Report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Neuroendocrine Tumor emerging therapies. 

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility. DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of Neuroendocrine tumors. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Neuroendocrine Tumor Drugs Market: Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Neuroendocrine Tumor Therapeutics Market Access and Reimbursement

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Neuroendocrine Tumor Therapeutics Market Report Scope

• The Neuroendocrine Tumor Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country-specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Neuroendocrine Tumor Treatment Market landscape.
• A detailed review of the Neuroendocrine Tumor Treatment Market, historical and forecasted Neuroendocrine Tumor Treatment Market Size, Neuroendocrine Tumor Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Neuroendocrine Tumor Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Neuroendocrine Tumor Drugs Market.

Neuroendocrine Tumor Treatment Market Report Insights

• Patient-based Neuroendocrine Tumor Market Forecasting
• Therapeutic Approaches
• Neuroendocrine Tumor Pipeline Drugs Analysis
• Neuroendocrine Tumor Treatment Market Size and Trends
• Existing and future Neuroendocrine Tumor Drugs Market Opportunity

Neuroendocrine Tumor Therapeutics Market Report Key Strengths

• 11 Years Neuroendocrine Tumor Market Forecast
• 7MM Coverage
• Neuroendocrine Tumor Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies
• Key Cross Competition
• Conjoint analysis
• Neuroendocrine Tumor Drugs Uptake
• Key Neuroendocrine Tumor Market Forecast Assumptions

Neuroendocrine Tumor Therapeutics Market Report Assessment

• Current Neuroendocrine Tumor Treatment Market Practices
• Neuroendocrine Tumor Unmet Needs
• Neuroendocrine Tumor Pipeline Drugs Profiles
• Neuroendocrine Tumor Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the growth rate of the 7MM Neuroendocrine Tumor Treatment Market?
• What was the Neuroendocrine Tumor Treatment Market Size, the Neuroendocrine Tumor Treatment Market Size by therapies, Neuroendocrine Tumor Drugs Market Share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the Neuroendocrine Tumor Treatment?
• How many companies are developing therapies for the Neuroendocrine Tumors Treatment?
• What are the recent novel therapies, targets, Neuroendocrine Tumor Mechanisms of Action, and technologies developed to overcome the limitations of existing therapies?
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to Buy

• The Neuroendocrine Tumor Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Neuroendocrine Tumor Drugs Market.
• Insights on patient burden/disease Neuroendocrine Tumor Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Neuroendocrine Tumor Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Neuroendocrine Tumor Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Neuroendocrine Tumor Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Stay Updated with us for Recent Articles

• Gastroenteropancreatic Neuroendocrine Tumours Market To Gain Substantial Momentum With Entrance of Novel Therapies
• Understanding Neuroendocrine Tumors (NETs): An In-Depth Look
• Neuroendocrine Tumors (NETs): Unraveling the Mystery of a Complex Cancer
• Unveiling the Future: Global Neuroendocrine Tumor Market Trends & Innovations
• Neuroendocrine Tumors Newsletter
• Latest DelveInsight Blogs